Next earnings date: 7 Aug 2025

TRxADE HEALTH, Inc. – NASDAQ:MEDS

Add to watchlist

$7.59

-9.35

-55.19%

Market closed

Open in 2 days

+159.82%

month

+67.39%

quarter

+5279.49%

year

Market Cap	13.28M
Enterprise value	5.75M

P/E	-0.41
EV/Sales	1.29
EV/EBITDA	-0.45
Price/Sales	2.99
Price/Book	0.90
PEG ratio	-0.02
EPS	-28.18

Revenue	N/A
EBITDA	-11.85M
Income	-25.65M
Revenue Q/Q	-100%
Revenue Y/Y	-36.28%

Profit margin	-576.07%
Oper. margin	-316.77%
Gross margin	-12.49%
EBIT margin	-316.77%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

TRxADE HEALTH, Inc. (NASDAQ:MEDS): Profit margin
Jun 2023	2.25M	-1.97M	-87.73%
Sep 2023	2.05M	-3.52M	-171.29%
Dec 2023	2.35M	-11.71M	-498.04%
Mar 2024	0	-8.43M

TRxADE HEALTH, Inc. (NASDAQ:MEDS): Debt to assets
Jun 2023	3744985	5.03M	134.57%
Sep 2023	21653843	10.09M	46.62%
Dec 2023	12532913	11.99M	95.67%
Mar 2024	16739269	3.12M	18.64%

TRxADE HEALTH, Inc. (NASDAQ:MEDS): Cash Flow
Jun 2023	328.56K	-51.80K	-725.28K
Sep 2023	-603.11K	-207.11K	114.95K
Dec 2023	-867.52K	-350K	1.33M
Mar 2024	-10.18M	27.43M	-13.89M

TRxADE HEALTH alternative data

TRxADE HEALTH, Inc. (NASDAQ:MEDS): Employee count
Aug 2023	33
Sep 2023	33
Oct 2023	33
Nov 2023	33
Dec 2023	33
Jan 2024	33
Feb 2024	33
Mar 2024	33
Apr 2024	33
May 2024	8
Jun 2024	8
Jul 2024	8

TRxADE HEALTH
Hedge Funds Holdings Q1 2023

1.05% -10.31%

of MEDS is owned by hedge funds

7 -7

hedge funds hold MEDS stock

85.85K -842.01K

shares is hold by hedge funds

MEDS hedge funds holdings changes

TRxADE HEALTH, Inc. (NASDAQ:MEDS): Insider trades (number of shares)
Period	Buy	Sel
May 2022	12000	0
Aug 2022	1500	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	25 Aug 2022	FELL DONALD G. director director	Common Stock	1,500	$1.08	$1,620
Purchase	20 May 2022	AJJARAPU SURENDRA K director, 10 perc..	Common stock	10,000	$1.3	$13,000
Purchase	12 May 2022	FELL DONALD G. director director	Common Stock	2,000	$1.26	$2,520
Sale	21 Jun 2021	PETERSON MICHAEL L director director	Common stock	900	$4.45	$4,005
Sale	19 Apr 2021	PETERSON MICHAEL L director director	Common stock	900	$4.68	$4,212
Sale	19 Apr 2021	PATEL PRASHANT director, 10 perc..	Common stock	7,500	$4.39	$32,910
Sale	14 Dec 2020	PETERSON MICHAEL L director director	Common stock	1,800	$5.26	$9,461
Sale	14 Dec 2020	FELL DONALD G. director director	Common stock	1,000	$2.65	$2,650
Sale	14 Dec 2020	PATEL PRASHANT director, 10 perc..	Common stock	7,500	N/A	N/A
Sale	14 Dec 2020	TENAERTS PAMELA director director	Common stock	800	N/A	N/A

TRxADE HEALTH
Earnings Call Transcripts

Quarter	Transcript
Q1 2023 15 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 27 Mar 2023	Q4 2022 Earnings Call Transcript
Q3 2022 8 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 25 Jul 2022	Q2 2022 Earnings Call Transcript

MEDS earnings call transcripts

TRxADE HEALTH
Executives

Insider	Age	Compensation
Mr. Surendra K. Ajjarapu (1971) Founder, Chairman, Chief Executive Officer, Treasurer & Sec.	54	$295,420
Mr. Prashant Patel (1974) Founder, Pres, Chief Operating Officer & Director	51	$150,410
Mr. Howard A. Doss (1954) Chief Financial Officer	71	$90,430

TRxADE HEALTH
Latest News

Friday, 20 September 2024
11:59	TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.	globenewswire.com
Monday, 5 August 2024
08:01	TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team	globenewswire.com
Friday, 26 July 2024
08:01	TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million	globenewswire.com
Tuesday, 9 July 2024
08:05	TRxADE Health, Inc. Announces Special Cash Dividend	globenewswire.com
Wednesday, 29 May 2024
16:05	TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q	globenewswire.com
Tuesday, 23 April 2024
16:05	TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K	globenewswire.com
Wednesday, 6 March 2024
08:05	TRxADE Health, Inc. Announces Special Cash Dividend	globenewswire.com
Tuesday, 20 February 2024
08:14	Why Is Trxade Health (MEDS) Stock Up 230% Today?	InvestorPlace
Monday, 31 July 2023
16:15	TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.	Accesswire
Tuesday, 27 June 2023
09:11	Why Is Trxade Health (MEDS) Stock Down 13% Today?	InvestorPlace
Thursday, 22 June 2023
13:27	TRxADE Health (MEDS) Stock Soars 60% on Reverse Split	InvestorPlace
Monday, 15 May 2023
22:30	TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript	Seeking Alpha
19:45	TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates	Zacks Investment Research
Friday, 5 May 2023
16:15	TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.	Accesswire
Tuesday, 25 April 2023
00:20	TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.	Accesswire
Monday, 27 March 2023
21:30	TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript	Seeking Alpha
19:47	TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Monday, 13 March 2023
16:00	TRxADE HEALTH, INC. to Report Q4 and Year-End 2022 Financial Results on Monday, March 27th at 5:30 p.m.	Accesswire
Thursday, 12 January 2023
13:33	All You Need to Know About TRxADE (MEDS) Rating Upgrade to Strong Buy	Zacks Investment Research
Thursday, 17 November 2022
13:32	All You Need to Know About TRxADE (MEDS) Rating Upgrade to Buy	Zacks Investment Research
Wednesday, 9 November 2022
11:43	7 Meme Stocks Smart Investors Shouldn't Touch With a 10-Foot Pole	InvestorPlace
Tuesday, 8 November 2022
00:42	TRxADE Health, Inc. (MEDS) Q3 2022 Earnings Call Transcript	Seeking Alpha
Monday, 7 November 2022
20:19	TRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Monday, 24 October 2022
15:30	TRxADE HEALTH, INC. to Report Third Quarter 2022 Financial Results on Monday, November 7th at 5:00 p.m.	Accesswire
Tuesday, 20 September 2022
15:27	3 High Volume Penny Stocks To Watch Before FOMC Meeting	PennyStocks
Monday, 25 July 2022
22:10	TRxADE HEALTH, Inc.'s (MEDS) CEO Suren Ajjarapu on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
19:20	TRxADE (MEDS) Reports Q2 Loss, Tops Revenue Estimates	Zacks Investment Research
Monday, 11 July 2022
16:30	TRxADE HEALTH, INC. to Report Second Quarter 2022 Financial Results on Monday, July 25th at 5:00 p.m.	Accesswire
Monday, 9 May 2022
20:25	TRxADE HEALTH, Inc. (MEDS) CEO Suren Ajjarapu on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
19:33	TRxADE (MEDS) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research

Frequently Asked Questions (FAQ)

What's the price of TRxADE HEALTH stock today?

One share of TRxADE HEALTH stock can currently be purchased for approximately $7.59.
When is TRxADE HEALTH's next earnings date?

TRxADE HEALTH, Inc. is estimated to report earnings on Thursday, 7 Aug 2025.
Does TRxADE HEALTH pay dividends?

Yes, TRxADE HEALTH pays dividends and its trailing 12-month yield is 230.57% with -50% payout ratio.It means that the company is paying a dividend while loss making. The last TRxADE HEALTH stock dividend of undefined was paid on 6 Sep 2025.
How much money does TRxADE HEALTH make?

TRxADE HEALTH has a market capitalization of 13.28M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 27.74% to 8.27M US dollars.
What is TRxADE HEALTH's stock symbol?

TRxADE HEALTH, Inc. is traded on the NASDAQ under the ticker symbol "MEDS".
What is TRxADE HEALTH's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of TRxADE HEALTH?

Shares of TRxADE HEALTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are TRxADE HEALTH's key executives?
TRxADE HEALTH's management team includes the following people:
- Mr. Surendra K. Ajjarapu Founder, Chairman, Chief Executive Officer, Treasurer & Sec.(age: 54, pay: $295,420)
- Mr. Prashant Patel Founder, Pres, Chief Operating Officer & Director(age: 51, pay: $150,410)
- Mr. Howard A. Doss Chief Financial Officer(age: 71, pay: $90,430)
Is TRxADE HEALTH founder-led company?

Yes, TRxADE HEALTH is a company led by its founders Mr. Surendra K. Ajjarapu and Mr. Prashant Patel.
How many employees does TRxADE HEALTH have?

As Jul 2024, TRxADE HEALTH employs 8 workers, which is 76% less then previous quarter.
When TRxADE HEALTH went public?

TRxADE HEALTH, Inc. is publicly traded company for more then 11 years since IPO on 6 Feb 2014.
What is TRxADE HEALTH's official website?

The official website for TRxADE HEALTH is trxadehealth.com.
Where are TRxADE HEALTH's headquarters?

TRxADE HEALTH is headquartered at 3840 Land O’ Lakes Boulevard, Land O'Lakes, FL.
How can i contact TRxADE HEALTH?

TRxADE HEALTH's mailing address is 3840 Land O’ Lakes Boulevard, Land O'Lakes, FL and company can be reached via phone at +800 2610281.

TRxADE HEALTH, Inc.

trxadehealth.com

Exchange:

NASDAQ

Full time employees:

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

+800 2610281

3840 Land O’ Lakes Boulevard
Land O'Lakes, FL 34639

CIK: 0001382574
ISIN: US89846A4058
CUSIP: 89846A207